| Year |
Citation |
Score |
| 2020 |
Hopkins AM, Kichenadasse G, Garrett-Mayer E, Karapetis CS, Rowland A, Sorich MJ. Development and validation of a prognostic model for patients with advanced lung cancer treated with the immune checkpoint inhibitor atezolizumab. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32086341 DOI: 10.1158/1078-0432.Ccr-19-2968 |
0.319 |
|
| 2020 |
Meiri E, Garrett-Mayer E, Halabi S, Mangat PK, Shrestha S, Ahn ER, Osayameh O, Perla V, Schilsky RL. Pembrolizumab (P) in patients (Pts) with colorectal cancer (CRC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Journal of Clinical Oncology. 38: 133-133. DOI: 10.1200/Jco.2020.38.4_Suppl.133 |
0.308 |
|
| 2020 |
Gupta R, Garrett-Mayer E, Halabi S, Mangat PK, D'Andre SD, Meiri E, Shrestha S, Warren SL, Ranasinghe S, Schilsky RL. Pertuzumab plus trastuzumab (P+T) in patients (Pts) with colorectal cancer (CRC) with ERBB2 amplification or overexpression: Results from the TAPUR Study. Journal of Clinical Oncology. 38: 132-132. DOI: 10.1200/Jco.2020.38.4_Suppl.132 |
0.331 |
|
| 2020 |
Klute K, Garrett-Mayer E, Halabi S, Mangat PK, Nazemzadeh R, Yost KJ, Butler NL, Perla V, Schilsky RL. Cobimetinib plus vemurafenib (C+V) in patients (Pts) with colorectal cancer (CRC) with BRAF V600E mutations: Results from the TAPUR Study. Journal of Clinical Oncology. 38: 122-122. DOI: 10.1200/Jco.2020.38.4_Suppl.122 |
0.31 |
|
| 2020 |
Kushi LH, Lasiter L, Belli AJ, Boyd M, Bruinooge SS, Christian J, Garrett-Mayer E, Hansen E, Honnold R, Pe Benito R, Natanzon Y, Sakoda L, Rivera DRR, Rhodes W, Robert NJ, et al. Trends in immunotherapy use in patients with advanced non-small cell lung cancer (aNSCLC) patients: Analysis of real-world data. Journal of Clinical Oncology. 38: e19311-e19311. DOI: 10.1200/Jco.2020.38.15_Suppl.E19311 |
0.338 |
|
| 2020 |
Smith ML, Railey E, White CB, Dieterich JS, Garrett-Mayer E, Bruinooge SS, Freedman AN, De Moor J, Gray SW. NGS testing use and results: A survey of U.S. oncologists. Journal of Clinical Oncology. 38: e19145-e19145. DOI: 10.1200/Jco.2020.38.15_Suppl.E19145 |
0.312 |
|
| 2020 |
Alpert A, Bruinooge SS, Dizon DS, Koronkowski B, Garrett-Mayer E, Meersman SC, Miller RS, Potter D, Komatsoulis GA. Identification of transgender people with cancer in electronic health records (EHR): Recommendations based on CancerLinQ observations. Journal of Clinical Oncology. 38: e19046-e19046. DOI: 10.1200/Jco.2020.38.15_Suppl.E19046 |
0.322 |
|
| 2020 |
Potter D, Kaltenbaugh M, Kabadi S, Taylor A, Pascual E, Koskimaki J, Brothers R, Stoeber P, Mena J, Garrett-Mayer E. Vital status ascertainment in cancerlinq discovery (CLQD): Improvement in mortality capture with a supplemental data source. Journal of Clinical Oncology. 38: 7064-7064. DOI: 10.1200/Jco.2020.38.15_Suppl.7064 |
0.316 |
|
| 2020 |
Ahn ER, Garrett-Mayer E, Halabi S, Mangat PK, Calfa CJ, Alva AS, Suhag VS, Hamid O, Dotan E, Yang ES, Alese OB, Yost KJ, Marr AS, Palmer MC, Thompson FL, et al. Olaparib (O) in patients (pts) with pancreatic cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. Journal of Clinical Oncology. 38: 4637-4637. DOI: 10.1200/Jco.2020.38.15_Suppl.4637 |
0.334 |
|
| 2020 |
Walter KR, Ford FE, Gregoski MJ, Kramer RM, Knight KD, Spruill L, Nogueira LM, Krisanits BA, Taylor MH, Rue ACL, Lilly MB, Ambs S, Chan K, Turner TF, Varner H, ... ... Garrett-Mayer E, et al. Abstract C024: Lifestyle-associated advanced glycation end products are elevated in ER+ positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention Cancer Epidemiology, Biomarkers & Prevention. 29. DOI: 10.1158/1538-7755.Disp18-C024 |
0.327 |
|
| 2019 |
Gilbert A, Kandhare P, Nakhmani A, Meersman SC, Garrett-Mayer E, Kaltenbaugh M, Burkard ME, Williams C, Azuero A, Bhatia S, Kenzik K, Rocque GB. Utilizing visualization to qualitatively evaluate electronic health record-derived database limitations. Journal of Clinical Oncology. 37: 317-317. DOI: 10.1200/Jco.2019.37.27_Suppl.317 |
0.326 |
|
| 2019 |
Harvey RD, Rubinstein WS, Ison G, Khozin S, Chen L, Miller RS, Jun M, Stepanski E, Hyde B, Uldrick TS, Komatsoulis GA, Roberts J, Garrett-Mayer E, Schilsky RL, Schenkel C, et al. Impact of broadening clinical trial eligibility criteria for advanced non-small cell lung cancer patients: Real-world analysis. Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.18_Suppl.Lba108 |
0.362 |
|
| 2019 |
Ahn ER, Mangat PK, Garrett-Mayer E, Halabi S, Dib EG, Haggstrom DE, Alguire KB, Alvarez RH, Calfa CJ, Cannon TL, Crilley PA, Gaba AG, Marr AS, Sangal A, Thota R, et al. Palbociclib (P) in patients (pts) with non-small cell lung cancer (NSCLC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Journal of Clinical Oncology. 37: 9041-9041. DOI: 10.1200/Jco.2019.37.15_Suppl.9041 |
0.33 |
|
| 2019 |
Somaiah N, Van Tine BA, Hill EG, Milhem MM, Schuetze S, Meyer CF, Reuben DY, Elias AD, Read WL, Chawla SP, Wahlquist AE, Garrett-Mayer E, Kraft AS. Phase II trial of gemcitabine (G) with pazopanib (P) or gemcitabine with docetaxel (T) in advanced soft tissue sarcoma (STS). Journal of Clinical Oncology. 37: 11008-11008. DOI: 10.1200/Jco.2019.37.15_Suppl.11008 |
0.302 |
|
| 2019 |
Fisher J, Garrett-Mayer E, Halabi S, Mangat PK, Alvarez RH, Cannon TL, Crilley P, Pollock T, Baghdadi TA, Cotta JA, Rygiel AL, Antonelli KR, Islam S, Bruinooge SS, Schilsky RL. Abstract CT135: Cetuximab (C) in patients (Pts) with breast cancer (BC) and non-small cell lung cancer (NSCLC) without reportedKRAS, NRAS, BRAFmutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct135 |
0.357 |
|
| 2018 |
Hobbs BP, Barata PC, Kanjanapan Y, Paller CJ, Perlmutter J, Pond GR, Prowell TM, Rubin EH, Seymour LK, Wages NA, Yap TA, Feltquate D, Garrett-Mayer E, Grossman W, Hong DS, et al. Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology. Journal of the National Cancer Institute. PMID 30561713 DOI: 10.1093/Jnci/Djy196 |
0.361 |
|
| 2018 |
Chiuzan C, Garrett-Mayer E, Nishimura M. An adaptive dose-finding design based on both safety and immunologic responses in cancer clinical trials. Statistics in Biopharmaceutical Research. 10: 185-195. PMID 30524665 DOI: 10.1080/19466315.2018.1462727 |
0.724 |
|
| 2018 |
Walter KR, Ford ME, Gregoski MJ, Kramer RM, Knight KD, Spruill L, Nogueira LM, Krisanits BA, Phan V, La Rue AC, Lilly MB, Ambs S, Chan K, Turner TF, Varner H, ... ... Garrett-Mayer E, et al. Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention. Breast Cancer Research and Treatment. PMID 30368741 DOI: 10.1007/S10549-018-4992-7 |
0.309 |
|
| 2018 |
Omuro A, Beal K, McNeill K, Young RJ, Thomas A, Lin X, Terziev R, Kaley TJ, DeAngelis LM, Daras M, Gavrilovic IT, Mellinghoff I, Diamond EL, McKeown A, Manne M, ... ... Garrett-Mayer E, et al. Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017769992. PMID 29683790 DOI: 10.1200/Jco.2017.76.9992 |
0.33 |
|
| 2018 |
Wrangle JM, Velcheti V, Patel MR, Garrett-Mayer E, Hill EG, Ravenel JG, Miller JS, Farhad M, Anderton K, Lindsey K, Taffaro-Neskey M, Sherman C, Suriano S, Swiderska-Syn M, Sion A, et al. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. The Lancet. Oncology. PMID 29628312 DOI: 10.1016/S1470-2045(18)30148-7 |
0.313 |
|
| 2018 |
Al Baghdadi T, Halabi S, Garrett-Mayer E, Mangat PK, Ahn ER, Sahai V, Alvarez RH, Kim ES, Yost KJ, Guo K, Rygiel AL, Antonelli KR, Butler NL, Bruinooge SS, Schilsky RL. Palbociclib (P) in patients (Pts) with pancreatic cancer (PC) and gallbladder or bile duct cancer (GBC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. Journal of Clinical Oncology. 36: 2532-2532. DOI: 10.1200/Jco.2018.36.15_Suppl.2532 |
0.323 |
|
| 2018 |
Barata P, Hobbs B, Rini B, Paller C, Normolle D, Garrett-Mayer E, Rubin E, Rosner G, Pond G, Perlmutter J, Seymour L, Siu L, Wages N, Ivy P, Prowell T, et al. Abstract A100: Seamless phase I/II clinical trials in oncology: retrospective analysis of the last 7 years Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-A100 |
0.359 |
|
| 2017 |
Kocher MR, Sharma A, Garrett-Mayer E, Ravenel JG. Pretreatment 18F-Fluorodeoxyglucose Positron Emission Tomography Standardized Uptake Values and Tumor Size in Medically Inoperable Nonsmall Cell Lung Cancer Is Prognostic of Overall 2-Year Survival After Stereotactic Body Radiation Therapy. Journal of Computer Assisted Tomography. PMID 29251647 DOI: 10.1097/Rct.0000000000000653 |
0.311 |
|
| 2017 |
Moore T, Wagner CR, Scurti GM, Hutchens KA, Godellas C, Clark AL, Kolawole EM, Hellman LM, Singh NK, Huyke FA, Wang SY, Calabrese KM, Embree HD, Orentas R, Shirai K, ... ... Garrett-Mayer E, et al. Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells. Cancer Immunology, Immunotherapy : Cii. PMID 29052782 DOI: 10.1007/S00262-017-2073-0 |
0.322 |
|
| 2017 |
Kim ES, Bruinooge SS, Roberts S, Ison G, Lin NU, Gore L, Uldrick TS, Lichtman SM, Roach N, Beaver JA, Sridhara R, Hesketh PJ, Denicoff AM, Garrett-Mayer E, Rubin E, et al. Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017737916. PMID 28968170 DOI: 10.1200/Jco.2017.73.7916 |
0.36 |
|
| 2017 |
Rachidi S, Metelli A, Riesenberg B, Wu BX, Nelson MH, Wallace C, Paulos CM, Rubinstein MP, Garrett-Mayer E, Hennig M, Bearden DW, Yang Y, Liu B, Li Z. Platelets subvert T cell immunity against cancer via GARP-TGFβ axis. Science Immunology. 2. PMID 28763790 DOI: 10.1126/Sciimmunol.Aai7911 |
0.305 |
|
| 2017 |
Britten CD, Thomas MB, Garrett-Mayer E, Chin SH, Shirai K, Ogretmen B, Bentz TA, Brisendine A, Anderton K, Cusack SL, Maines LW, Zhuang Y, Smith CD. A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28420720 DOI: 10.1158/1078-0432.Ccr-16-2363 |
0.321 |
|
| 2017 |
Coaxum SD, Tiedeken J, Garrett-Mayer E, Myers J, Rosenzweig SA, Neskey DM. The tumor suppressor capability of p53 is dependent on non-muscle myosin IIA function in head and neck cancer. Oncotarget. PMID 28160562 DOI: 10.18632/Oncotarget.14967 |
0.303 |
|
| 2016 |
Metelli A, Wu BX, Fugle CW, Rachidi S, Sun S, Zhang Y, Wu J, Tomlinson S, Howe PH, Yang Y, Garrett-Mayer E, Liu B, Li Z. Surface Expression of TGFβ Docking Receptor GARP Promotes Oncogenesis and Immune Tolerance in Breast Cancer. Cancer Research. PMID 27913437 DOI: 10.1158/0008-5472.Can-16-1456 |
0.333 |
|
| 2016 |
Visvanathan K, Fackler MS, Zhang Z, Lopez-Bujanda ZA, Jeter SC, Sokoll LJ, Garrett-Mayer E, Cope LM, Umbricht CB, Euhus DM, Forero A, Storniolo AM, Nanda R, Lin NU, Carey LA, et al. Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2015662080. PMID 27870562 DOI: 10.1200/Jco.2015.66.2080 |
0.332 |
|
| 2016 |
Scheffel MJ, Scurti G, Simms P, Garrett-Mayer E, Mehrotra S, Nishimura MI, Voelkel-Johnson C. Efficacy of Adoptive T-cell Therapy Is Improved by Treatment with the Antioxidant N-Acetyl Cysteine, Which Limits Activation-Induced T-cell Death. Cancer Research. 76: 6006-6016. PMID 27742673 DOI: 10.1158/0008-5472.Can-16-0587 |
0.307 |
|
| 2016 |
Guest ST, Kratche ZR, Irish JC, Wilson RC, Haddad R, Gray JW, Garrett-Mayer E, Ethier SP. Functional oncogene signatures guide rationally designed combination therapies to synergistically induce breast cancer cell death. Oncotarget. PMID 27153554 DOI: 10.18632/Oncotarget.9147 |
0.346 |
|
| 2015 |
Venant H, Rahmaniyan M, Jones EE, Lu P, Lilly MB, Garrett-Mayer E, Drake RR, Kraveka JM, Smith CD, Voelkel-Johnson C. The sphingosine kinase 2 inhibitor ABC294640 reduces the growth of prostate cancer cells and results in accumulation of dihydroceramides in vitro and in vivo. Molecular Cancer Therapeutics. PMID 26494858 DOI: 10.1158/1535-7163.Mct-15-0279 |
0.304 |
|
| 2015 |
Chiuzan C, Garrett-Mayer E, Yeatts SD. A likelihood-based approach for computing the operating characteristics of the 3+3 phase I clinical trial design with extensions to other A+B designs. Clinical Trials (London, England). 12: 24-33. PMID 25349178 DOI: 10.1177/1740774514555585 |
0.702 |
|
| 2015 |
Thomas MB, Garrett-Mayer E, Anis M, Anderton KR, Bentz TA, Adelman AR, Brisendine A, Duddalwar V, Weiss GR, Siegel AB, Bendell JC, Baron AD, El-Khoueiry AB. A randomized phase II open label multi-institution study of the combination of bevacizumab (B) and erlotinib (E) compared to sorafenib (S) in the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC). Journal of Clinical Oncology. 33: 337-337. DOI: 10.1200/Jco.2015.33.3_Suppl.337 |
0.303 |
|
| 2015 |
Regan C, Clark J, Moore T, Moxley K, Scurti G, Lau Clark A, Dropulic B, Embree H, Shirai K, Garrett-Mayer E, Li M, Tobin Vealey K, Eby JM, Le Poole C, Nishimura M. T-cell therapy in metastatic melanoma: TIL 1383I TCR transduced T cells after infusion and activity in vivo. Journal of Clinical Oncology. 33: 3043-3043. DOI: 10.1200/Jco.2015.33.15_Suppl.3043 |
0.31 |
|
| 2015 |
Reed SG, Cunningham JE, Garrett-Mayer E, Mulligan JL, Fields LD, Boyle LR, Daanen SP, Keller JH, Roach CL, Pasquini WC, Lawrence L, Harmon H, Garrett AR, Wargovich MJ, Sharma AK. Abstract CT122: RCT of an herbal mouthrinse for radiotherapy induced oral mucositis in cancer patients Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Ct122 |
0.35 |
|
| 2015 |
Cooper SL, Hoover K, Garrett-Mayer E, Cummings KM, Carpenter MJ, Crowley K, Marshall DT, Warren GW. Abstract 3736: Assessment of tobacco use within 30 days increases referral for cessation support Cancer Research. 75: 3736-3736. DOI: 10.1158/1538-7445.Am2015-3736 |
0.307 |
|
| 2014 |
Turner-Ivey B, Guest ST, Irish JC, Kappler CS, Garrett-Mayer E, Wilson RC, Ethier SP. KAT6A, a chromatin modifier from the 8p11-p12 amplicon is a candidate oncogene in luminal breast cancer. Neoplasia (New York, N.Y.). 16: 644-55. PMID 25220592 DOI: 10.1016/J.Neo.2014.07.007 |
0.32 |
|
| 2014 |
Chen G, Gupta R, Petrik S, Laiko M, Leatherman JM, Asquith JM, Daphtary MM, Garrett-Mayer E, Davidson NE, Hirt K, Berg M, Uram JN, Dauses T, Fetting J, Duus EM, et al. A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer. Cancer Immunology Research. 2: 949-61. PMID 25116755 DOI: 10.1158/2326-6066.Cir-14-0058 |
0.322 |
|
| 2014 |
Ellis LM, Bernstein DS, Voest EE, Berlin JD, Sargent D, Cortazar P, Garrett-Mayer E, Herbst RS, Lilenbaum RC, Sima C, Venook AP, Gonen M, Schilsky RL, Meropol NJ, Schnipper LE. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 1277-80. PMID 24638016 DOI: 10.1200/Jco.2013.53.8009 |
0.312 |
|
| 2014 |
Esnaola NF, Chaudhary UB, O'Brien P, Garrett-Mayer E, Camp ER, Thomas MB, Cole DJ, Montero AJ, Hoffman BJ, Romagnuolo J, Orwat KP, Marshall DT. Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer. International Journal of Radiation Oncology, Biology, Physics. 88: 837-44. PMID 24606850 DOI: 10.1016/J.Ijrobp.2013.12.030 |
0.336 |
|
| 2014 |
Ford ME, Burshell D, Mack F, Wei W, Garrett-Mayer E. Abstract A65: Evaluating the reliability of an instrument assessing cancer clinical trial perceptions in a predominantly African American sample Cancer Epidemiology, Biomarkers & Prevention. 23. DOI: 10.1158/1538-7755.Disp13-A65 |
0.333 |
|
| 2014 |
Guest S, Irish J, Kratche Z, Garrett-Mayer E, Wilson R, Ethier S. Abstract 440: The TRiC chaperonin in breast cancer cell growth, survival and response to taxane therapy Cancer Research. 74: 440-440. DOI: 10.1158/1538-7445.Am2014-440 |
0.346 |
|
| 2013 |
Rudek MA, Connolly RM, Hoskins JM, Garrett-Mayer E, Jeter SC, Armstrong DK, Fetting JH, Stearns V, Wright LA, Zhao M, Watkins SP, McLeod HL, Davidson NE, Wolff AC. Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer. Breast Cancer Research and Treatment. 139: 135-43. PMID 23588952 DOI: 10.1007/S10549-013-2516-Z |
0.364 |
|
| 2013 |
Hudspeth MP, Heath TS, Chiuzan C, Garrett-Mayer E, Nista E, Burton L, Ragucci D. Folinic acid administration after MTX GVHD prophylaxis in pediatric allo-SCT. Bone Marrow Transplantation. 48: 46-9. PMID 22609886 DOI: 10.1038/Bmt.2012.82 |
0.302 |
|
| 2013 |
Thomas MB, Britten CD, Garrett-Mayer E, Chin SH, Bentz TA, Brisendine A, Matson TL, Cusack S, Maines LW, Zhuang Y, Smith CD. Abstract C62: Phase I trial of ABC294640, a first-in-class sphingosine kinase-2 inhibitor. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C62 |
0.395 |
|
| 2013 |
Garrett-Mayer E. Abstract ES03-3: Clinical 101: Clinical trial endpoints: Selection, analysis and interpretation Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-Es03-3 |
0.326 |
|
| 2012 |
Ford M, Wahlquist A, Blake R, Green C, Streets J, Fuller E, Johnson E, Jefferson M, Etheredge J, Varner H, Johnson S, Glover S, Turner D, Garrett-Mayer E. Assessing an intervention to improve clinical trial perceptions among predominately African-American communities in South Carolina. Progress in Community Health Partnerships : Research, Education, and Action. 6: 249-63. PMID 22982839 DOI: 10.1353/Cpr.2012.0038 |
0.31 |
|
| 2012 |
Burton JH, Garrett-Mayer E, Thamm DH. Evaluation of a 15-week CHOP protocol for the treatment of canine multicentric lymphoma. Veterinary and Comparative Oncology. 11: 306-15. PMID 22548975 DOI: 10.1111/J.1476-5829.2012.00324.X |
0.324 |
|
| 2012 |
Van Meter EM, Garrett-Mayer E, Bandyopadhyay D. Dose-finding clinical trial design for ordinal toxicity grades using the continuation ratio model: an extension of the continual reassessment method. Clinical Trials (London, England). 9: 303-13. PMID 22547420 DOI: 10.1177/1740774512443593 |
0.757 |
|
| 2012 |
Kaseb AO, Garrett-Mayer E, Morris JS, Xiao L, Lin E, Onicescu G, Hassan MM, Hassabo HM, Iwasaki M, Deaton FL, Abbruzzese JL, Thomas MB. Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial. Oncology. 82: 67-74. PMID 22327795 DOI: 10.1159/000335963 |
0.312 |
|
| 2011 |
Shirai K, Saddoughi S, O'Brien PE, Afrin L, Garrett-Mayer E, Simon GR, Chaudhary UB, Ogretmen B. Serum C18-ceramide as a biomarker for response: Phase II trial of gemcitabine plus doxorubicin in patients with HNSCC. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 5590. PMID 28022062 DOI: 10.1200/Jco.2011.29.15_Suppl.5590 |
0.326 |
|
| 2011 |
Connolly RM, Rudek MA, Mc Leod HL, Garrett-Mayer E, Jeter SC, Wright LA, Stearns V, Armstrong DK, Fetting JH, Watkins SP, Davidson NE, Wolff AC. A phase II pharmacokinetic/pharmacogenetic (PK/PG) study using fixed-dose capecitabine in metastatic breast cancer (MBC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 1067. PMID 28020631 DOI: 10.1200/Jco.2011.29.15_Suppl.1067 |
0.32 |
|
| 2011 |
Tanner NT, Watson P, Boylan A, Memoli JS, Pastis N, Taylor K, Garrett-Mayer E, Silvestri GA. Utilizing endobronchial ultrasound with fine-needle aspiration to obtain tissue for molecular analysis: a single-center experience. Journal of Bronchology & Interventional Pulmonology. 18: 317-21. PMID 23208625 DOI: 10.1097/Lbr.0B013E3182341B07 |
0.316 |
|
| 2011 |
Saddoughi SA, Garrett-Mayer E, Chaudhary U, O'Brien PE, Afrin LB, Day TA, Gillespie MB, Sharma AK, Wilhoit CS, Bostick R, Senkal CE, Hannun YA, Bielawski J, Simon GR, Shirai K, et al. Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum Câ‚₈-ceramide as a novel biomarker for monitoring response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 6097-105. PMID 21791630 DOI: 10.1158/1078-0432.Ccr-11-0930 |
0.344 |
|
| 2011 |
Solito S, Falisi E, Diaz-Montero CM, Doni A, Pinton L, Rosato A, Francescato S, Basso G, Zanovello P, Onicescu G, Garrett-Mayer E, Montero AJ, Bronte V, Mandruzzato S. A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood. 118: 2254-65. PMID 21734236 DOI: 10.1182/Blood-2010-12-325753 |
0.31 |
|
| 2011 |
Kraft AS, Garrett-Mayer E, Wahlquist AE, Golshayan A, Chen CS, Butler W, Bearden J, Lilly M. Combination therapy of recurrent prostate cancer with the proteasome inhibitor bortezomib plus hormone blockade. Cancer Biology & Therapy. 12: 119-24. PMID 21532336 DOI: 10.4161/Cbt.12.2.15723 |
0.326 |
|
| 2011 |
Connolly RM, Rudek MA, Garrett-Mayer E, Jeter SC, Donehower MG, Wright LA, Zhao M, Fetting JH, Emens LA, Stearns V, Davidson NE, Baker SD, Wolff AC. Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer. Breast Cancer Research and Treatment. 127: 153-62. PMID 21350820 DOI: 10.1007/S10549-011-1413-6 |
0.347 |
|
| 2011 |
Van Meter EM, Garrett-Mayer E, Bandyopadhyay D. Proportional odds model for dose-finding clinical trial designs with ordinal toxicity grading. Statistics in Medicine. 30: 2070-80. PMID 21344472 DOI: 10.1002/Sim.4069 |
0.759 |
|
| 2011 |
Gemmill RM, Roche J, Potiron VA, Nasarre P, Mitas M, Coldren CD, Helfrich BA, Garrett-Mayer E, Bunn PA, Drabkin HA. ZEB1-responsive genes in non-small cell lung cancer. Cancer Letters. 300: 66-78. PMID 20980099 DOI: 10.1016/J.Canlet.2010.09.007 |
0.3 |
|
| 2011 |
Rhome R, Wahlquist A, Garrett-Mayer E, Harper J. P1-11-05: Investigation of Epidemiological Factors as Barriers to Indicated Radiation Therapy in Post-Mastectomy Breast Cancer Patients in South Carolina. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P1-11-05 |
0.342 |
|
| 2010 |
Watkins JM, Wahlquist AE, Zauls AJ, Fields EC, Garrett-Mayer E, Aguero EG, Silvestri GA, Sharma AK. High-dose fractionated radiotherapy to 80 Gy for stage I-II medically inoperable non-small-cell lung cancer. Journal of Medical Imaging and Radiation Oncology. 54: 554-61. PMID 21199434 DOI: 10.1111/J.1754-9485.2010.02213.X |
0.342 |
|
| 2010 |
Watkins JM, Wahlquist AE, Zauls AJ, Shirai K, Garrett-Mayer E, Aguero EG, Silvestri GA, Sherman CA, Sharma AK. Involved-field radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer: disease control, patterns of failure and survival. Journal of Medical Imaging and Radiation Oncology. 54: 483-9. PMID 20958948 DOI: 10.1111/J.1754-9485.2010.02201.X |
0.336 |
|
| 2010 |
Watkins JM, Fortney JA, Wahlquist AE, Shirai K, Garrett-Mayer E, Aguero EG, Sherman CA, Turrisi AT, Sharma AK. Once-daily radiotherapy to > or =59.4 Gy versus twice-daily radiotherapy to > or =45.0 Gy with concurrent chemotherapy for limited-stage small-cell lung cancer: a comparative analysis of toxicities and outcomes. Japanese Journal of Radiology. 28: 340-8. PMID 20585921 DOI: 10.1007/S11604-010-0429-X |
0.358 |
|
| 2010 |
Ivy SP, Siu LL, Garrett-Mayer E, Rubinstein L. Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 1726-36. PMID 20215542 DOI: 10.1158/1078-0432.Ccr-09-1961 |
0.369 |
|
| 2010 |
Ruppert BN, Watkins JM, Shirai K, Wahlquist AE, Garrett-Mayer E, Aguero EG, Sherman CA, Reed CE, Sharma AK. Cisplatin/Irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer. American Journal of Clinical Oncology. 33: 346-52. PMID 19841574 DOI: 10.1097/Coc.0B013E3181Aaca26 |
0.351 |
|
| 2010 |
Montero A, Diaz C, Slingerland J, Pegram M, Hurley J, Welsh C, Avisar E, Seo P, Vogel C, Garrett-Mayer E, Hermann V, Baker M, Silva O, Koniaris L, Rodgers S, et al. Abstract P1-11-05: Phase 2 Study of Neoadjuvant Treatment with Cellular Redox Modulator NOV-002 in Combination with Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) in Patients with Stage II-III HER-2 (-) Breast Cancer Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P1-11-05 |
0.392 |
|
| 2009 |
Zellars RC, Stearns V, Frassica D, Asrari F, Tsangaris T, Myers L, DiPasquale S, Lange JR, Jacobs LK, Emens LA, Armstrong DK, Fetting JH, Garrett-Mayer E, Davidson NE, Wolff AC. Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2816-22. PMID 19332718 DOI: 10.1200/Jco.2008.20.0139 |
0.352 |
|
| 2009 |
Watkins JM, Shirai KS, Wahlquist AE, Stuart RK, Chaudhary UB, Garrett-Mayer E, Day TA, Gillespie MB, Sharma AK. Toxicity and survival outcomes of hyperfractionated split-course reirradiation and daily concurrent chemotherapy in locoregionally recurrent, previously irradiated head and neck cancers. Head & Neck. 31: 493-502. PMID 19156831 DOI: 10.1002/Hed.20986 |
0.321 |
|
| 2009 |
Karp JE, Flatten K, Feldman EJ, Greer JM, Loegering DA, Ricklis RM, Morris LE, Ritchie E, Smith BD, Ironside V, Talbott T, Roboz G, Le SB, Meng XW, Schneider PA, ... ... Garrett-Mayer E, et al. Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide. Blood. 113: 4841-52. PMID 19109557 DOI: 10.1182/Blood-2008-08-172726 |
0.31 |
|
| 2009 |
Watkins JM, Wahlquist AE, Shirai K, Garrett-Mayer E, Aguero EG, Fortney JA, Sherman CA, Sharma AK. Factors associated with severe acute esophagitis from hyperfractionated radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer. International Journal of Radiation Oncology, Biology, Physics. 74: 1108-13. PMID 19084345 DOI: 10.1016/J.Ijrobp.2008.09.013 |
0.33 |
|
| 2009 |
Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunology, Immunotherapy : Cii. 58: 49-59. PMID 18446337 DOI: 10.1007/S00262-008-0523-4 |
0.366 |
|
| 2009 |
Zauls AJ, Watkins JM, Wahlquist AH, Shirai K, Garrett-Mayer E, Aguero EG, Silvestri GA, Sherman CA, Sharma AK. Involved-Field Radiotherapy With Concurrent Chemotherapy for Limited-Stage Small-Cell Lung Cancer: Patterns of Failure, Disease Control, and Survival Clinical Lung Cancer. 10. DOI: 10.3816/Clc.2009.N.073 |
0.309 |
|
| 2009 |
Watkins JM, Wahlquist AE, Zauls AJ, Batchelor EC, Garrett-Mayer E, Aguero EG, Silvestri GA, Sharma AK. High-Dose Fractionated Radiotherapy to 80 Gy for Medically Inoperable Non–Small-Cell Lung Cancer: Experience of 100 Tumors in 98 Patients Clinical Lung Cancer. 10. DOI: 10.3816/Clc.2009.N.072 |
0.331 |
|
| 2009 |
Harper J, Watkins J, Baker M, Cole D, Dragun A, Garrett-Mayer E, Wahlquist A, Jenrette J. Long term disease control outcomes for partial breast irradiation using MammoSite brachytherapy. Cancer Research. 69: 5145. DOI: 10.1158/0008-5472.Sabcs-5145 |
0.32 |
|
| 2009 |
Diaz-Montero C, Paphitis N, Onicescu G, Zhu Y, Verma N, Garrett-Mayer E, Schuhwerk K, Pazoles C, Glück S, Montero A. Daily injections of the glutathione disulfide mimetic NOV-002 ameliorates hematologic toxicities from neoadjuvant chemotherapy in breast cancer patients enrolled in the NEO-NOVO trial, and significantly increases circulating dendritic cells. Cancer Research. 69: 2141. DOI: 10.1158/0008-5472.Sabcs-2141 |
0.357 |
|
| 2009 |
Marshall DT, O'Brien P, Hoffman B, Garrett-Mayer E, Chaudhary U, Brisendine A, Jones BD, Terwilliger LE, Cranford K, Esnaola N. IMRT to Reduce Toxicity in Chemoradiation for Locally Advanced Pancreatic Cancer - Preliminary Results of a Phase II Trial International Journal of Radiation Oncology Biology Physics. 75. DOI: 10.1016/J.Ijrobp.2009.07.615 |
0.333 |
|
| 2008 |
Jimeno A, Rudek MA, Kulesza P, Ma WW, Wheelhouse J, Howard A, Khan Y, Zhao M, Jacene H, Messersmith WA, Laheru D, Donehower RC, Garrett-Mayer E, Baker SD, Hidalgo M. Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 4172-9. PMID 18757332 DOI: 10.1200/Jco.2008.16.2347 |
0.324 |
|
| 2008 |
Blum C, Graham A, Yousefzadeh M, Shrout J, Benjamin K, Krishna M, Hoda R, Hoda R, Cole DJ, Garrett-Mayer E, Reed C, Wallace M, Mitas M. The expression ratio of Map7/B2M is prognostic for survival in patients with stage II colon cancer. International Journal of Oncology. 33: 579-84. PMID 18695889 DOI: 10.3892/Ijo_00000043 |
0.327 |
|
| 2008 |
Moussa O, Ashton AW, Fraig M, Garrett-Mayer E, Ghoneim MA, Halushka PV, Watson DK. Novel role of thromboxane receptors beta isoform in bladder cancer pathogenesis. Cancer Research. 68: 4097-104. PMID 18519668 DOI: 10.1158/0008-5472.Can-07-6560 |
0.304 |
|
| 2008 |
Karp JE, Smith BD, Gojo I, Lancet JE, Greer J, Klein M, Morris L, Levis MJ, Gore SD, Wright JJ, Garrett-Mayer E. Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 3077-82. PMID 18483374 DOI: 10.1158/1078-0432.Ccr-07-4743 |
0.339 |
|
| 2008 |
Reed CE, Graham A, Hoda RS, Khoor A, Garrett-Mayer E, Wallace MB, Mitas M. A simple two-gene prognostic model for adenocarcinoma of the lung. The Journal of Thoracic and Cardiovascular Surgery. 135: 627-34. PMID 18329483 DOI: 10.1016/J.Jtcvs.2007.10.058 |
0.314 |
|
| 2008 |
Abukhdeir AM, Vitolo MI, Argani P, De Marzo AM, Karakas B, Konishi H, Gustin JP, Lauring J, Garay JP, Pendleton C, Konishi Y, Blair BG, Brenner K, Garrett-Mayer E, Carraway H, et al. Tamoxifen-stimulated growth of breast cancer due to p21 loss. Proceedings of the National Academy of Sciences of the United States of America. 105: 288-93. PMID 18162533 DOI: 10.1073/Pnas.0710887105 |
0.303 |
|
| 2008 |
Chaudhary UB, Gudena V, Milling DL, O'Brien P, Montero AJ, Brashears J, Marshall D, Hoffman B, Garrett-Mayer E, Esnaola N. Preliminary results of a phase II neoadjuvant trial with gemcitabine/oxaliplatin and cetuximab followed by surgery or concurrent intensity modulated radiation therapy (IMRT) with capecitabine for patients with borderline resectable and unresectable nonmetastatic pancreatic cancer Journal of Clinical Oncology. 26: 15506-15506. DOI: 10.1200/Jco.2008.26.15_Suppl.15506 |
0.325 |
|
| 2008 |
Shirai K, Watkins JM, Herrin AE, Garrett-Mayer E, Aguero EG, Shernan CA, Sharma AK. Impact of Treatment Duration and Delays on In-field Disease Control for Twice-daily Radiotherapy (BID-RT) with Concurrent Chemotherapy in Limited-stage Small-cell Lung Cancer (SCLC) International Journal of Radiation Oncology Biology Physics. 72. DOI: 10.1016/J.Ijrobp.2008.06.406 |
0.318 |
|
| 2007 |
Beldner MA, Sherman CA, Green MR, Garrett-Mayer E, Chaudhary U, Meyer ML, Kraft AS, Montero AJ. Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer. Bmc Cancer. 7: 231. PMID 18096059 DOI: 10.1186/1471-2407-7-231 |
0.369 |
|
| 2007 |
Jimeno A, Hallur G, Chan A, Zhang X, Cusatis G, Chan F, Shah P, Chen R, Hamel E, Garrett-Mayer E, Khan S, Hidalgo M. Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein tau is predictive of their activity in pancreatic cancer. Molecular Cancer Therapeutics. 6: 1509-16. PMID 17483439 DOI: 10.1158/1535-7163.Mct-06-0592 |
0.311 |
|
| 2007 |
Bajaj GK, Zhang Z, Garrett-Mayer E, Drew R, Sinibaldi V, Pili R, Denmeade SR, Carducci MA, Eisenberger MA, DeWeese TL. Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy. Urology. 69: 526-31. PMID 17382158 DOI: 10.1016/J.Urology.2006.12.006 |
0.302 |
|
| 2007 |
Cornblatt BS, Ye L, Dinkova-Kostova AT, Erb M, Fahey JW, Singh NK, Chen MSA, Stierer T, Garrett-Mayer E, Argani P, Davidson NE, Talalay P, Kensler TW, Visvanathan K. Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast Carcinogenesis. 28: 1485-1490. PMID 17347138 DOI: 10.1093/Carcin/Bgm049 |
0.326 |
|
| 2007 |
Lancet JE, Gojo I, Gotlib J, Feldman EJ, Greer J, Liesveld JL, Bruzek LM, Morris L, Park Y, Adjei AA, Kaufmann SH, Garrett-Mayer E, Greenberg PL, Wright JJ, Karp JE. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood. 109: 1387-94. PMID 17082323 DOI: 10.1182/Blood-2006-04-014357 |
0.309 |
|
| 2007 |
Zellars RC, Frassica D, Stearns V, Asrari F, Fetting JH, Armstrong DK, Myers L, Tsangaris T, Garrett-Mayer E, Wolff AC. Phase I/II Trial of Partial Breast Irradiation With Concurrent Dose-Dense Doxorubicin and Cyclophosphamide (ddAC) Chemotherapy in Early Stage Breast Cancer: Report of Skin Toxicity and Cosmetic Outcome International Journal of Radiation Oncology Biology Physics. 69. DOI: 10.1016/J.Ijrobp.2007.07.046 |
0.339 |
|
| 2006 |
Garrett-Mayer E. The continual reassessment method for dose-finding studies: a tutorial. Clinical Trials (London, England). 3: 57-71. PMID 16539090 DOI: 10.1191/1740774506Cn134Oa |
0.316 |
|
| 2006 |
Murata S, Kominsky SL, Vali M, Zhang Z, Garrett-Mayer E, Korz D, Huso D, Baker SD, Barber J, Jaffee E, Reilly RT, Sukumar S. Ductal access for prevention and therapy of mammary tumors Cancer Research. 66: 638-645. PMID 16423990 DOI: 10.1158/0008-5472.Can-05-4329 |
0.326 |
|
| 2006 |
Lo PK, Mehrotra J, D'Costa A, Fackler MJ, Garrett-Mayer E, Argani P, Sukumar S. Epigenetic suppression of secreted frizzled related protein 1 (SFRP1) expression in human breast cancer. Cancer Biology & Therapy. 5: 281-6. PMID 16410723 DOI: 10.4161/Cbt.5.3.2384 |
0.311 |
|
| 2006 |
Sinibaldi VJ, Carducci MA, Elza-Brown K, Rosenbaum E, Denmeade S, Pili R, Walczak J, Garrett-Mayer E, Moore-Cooper S, Eisenberger MA. A phase II evaluation of imatinib mesylate (G) in stage M0 prostate cancer (PC) patients (pts) on hormonal therapy (HT) with evidence of biochemical relapse Journal of Clinical Oncology. 24: 14612-14612. DOI: 10.1200/Jco.2006.24.18_Suppl.14612 |
0.315 |
|
| Show low-probability matches. |